AboutValuesWhy OA.mg?OA.mg PremiumExploreDataContact
Chrome ExtensionScholarMindChatGPT Plugin
ϟ
 
DOI: 10.1016/j.ahj.2015.03.004
¤ OpenAccess: Hybrid
This work has “Hybrid” OA status. This means it is free under an open license in a toll-access journal.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

Dean J. Kereiakes,Jennifer G. Robinson,Christopher P. Cannon,Christelle Lorenzato,Robert Pordy,Umesh Chaudhari,Helen M. Colhoun

Alirocumab
Medicine
Placebo
2015
Loading...
    Cite this:
Generate Citation
Powered by Citationsy*
    “Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study” is a paper by Dean J. Kereiakes Jennifer G. Robinson Christopher P. Cannon Christelle Lorenzato Robert Pordy Umesh Chaudhari Helen M. Colhoun published in 2015. It has an Open Access status of “hybrid”. You can read and download a PDF Full Text of this paper here.
    OA.mgAbout UsOur ValuesWhy OA.mg? OA.mg PremiumChrome ExtensionChatGPT PluginPublic RoadmapChangelogContact UsFeedback?
    Privacy PolicyTerms of ServiceRefund Policy
    ContentOA.mg CoverageTop ListsOpen Access JournalsTopicsBlog
    ExploreGeographyEngineeringPoliSciGeologyPhilosophySociologyArtHistoryMathematicsPhysics
     PsychologyComputer ScienceBusinessEnvironmental ScienceChemistryMaterials ScienceMedicineBiologyEconomics
    OA.mg is built in Stockholm, London, and Seoul. We work hand in hand with the scientific community to advance the cause of Open Access. Feedback makes us better.